Vincenzo Di Noia

Bergamo, 24125, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).

Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 09, 2025

LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-Programmed Cell Death Protein 1 or Anti-Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy.

LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti-Programmed Cell Death Protein 1 or Anti-Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: February 25, 2025

Malignant Pleural Mesothelioma: A 2025 Update.

Malignant Pleural Mesothelioma: A 2025 Update.

Journal: Journal of clinical medicine

Published: January 18, 2025

Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed?

Duration of humoral response to the third dose of BNT162b2 vaccine in patients with solid cancer: Is fourth dose urgently needed?

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 04, 2022

Potentiation of humoral response to the BNT162b2 vaccine after the third dose in patients with solid cancer.

Potentiation of humoral response to the BNT162b2 vaccine after the third dose in patients with solid cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 18, 2022

Rapid decline of humoral response to two doses of BNT162b2 vaccine in patients with solid cancer after six months: The urgent need of the additional dose!

Rapid decline of humoral response to two doses of BNT162b2 vaccine in patients with solid cancer after six months: The urgent need of the additional dose!

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 26, 2021

Clinical characteristics limiting the durability of humoral response to BNT162b2 in patients with solid cancer.

Clinical characteristics limiting the durability of humoral response to BNT162b2 in patients with solid cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 11, 2021

Reply to the letter entitled: Re: The first report on Covid-19 vaccine refusal by patients with cancer in Italy: Early data from a single-institute survey.

Reply to the letter entitled: Re: The first report on Covid-19 vaccine refusal by patients with cancer in Italy: Early data from a single-institute survey.

Journal: European journal of cancer (Oxford, England : 1990)

Published: September 07, 2021

Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers.

Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers.

Journal: Vaccines

Published: August 17, 2021

Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.

Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation.

Journal: Cancer immunology, immunotherapy : CII

Published: July 06, 2021

Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution.

Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 01, 2021

Corrigendum to 'The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer': [ESMO Open Volume 6, Issue 2, April 2021, 100078].

Corrigendum to 'The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer': [ESMO Open Volume 6, Issue 2, April 2021, 100078].

Journal: ESMO open

Published: June 19, 2021

Showing 1-12 of 40

Last Updated: 09/26/2026